IQVIA (IQV) 10-Q 3 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 26, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	Q
Entity Registrant Name	Quintiles Transnational Holdings Inc.
Entity Central Index Key	1,478,242
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		119,668,196

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Service revenues	$ 1,108,022	$ 1,029,974
Reimbursed expenses	382,063	317,619
Total revenues	1,490,085	1,347,593
Costs of revenue, service costs	700,566	661,827
Costs of revenue, reimbursed expenses	382,063	317,619
Selling, general and administrative	225,516	219,606
Restructuring costs	3,144	5,324
Income from operations	178,796	143,217
Interest income	(630)	(870)
Interest expense	25,959	25,340
Other expense (income), net	4,506	(2,861)
Income before income taxes and equity in earnings of unconsolidated affiliates	148,961	121,608
Income tax expense	42,577	36,088
Income before equity in earnings of unconsolidated affiliates	106,384	85,520
Equity in earnings of unconsolidated affiliates	2,642	911
Net income	109,026	86,431
Net income attributable to noncontrolling interests	(2,358)	(33)
Net income attributable to Quintiles Transnational Holdings Inc.	$ 106,668	$ 86,398
Earnings per share attributable to common shareholders:
Basic	$ 0.89	$ 0.69
Diluted	$ 0.88	$ 0.68
Weighted average common shares outstanding:
Basic	119,448	124,504
Diluted	121,438	127,454

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 109,026	$ 86,431
Comprehensive income adjustments:
Unrealized losses on available-for-sale securities, net of income taxes of ($56) and ($104)	(90)	(165)
Unrealized losses on derivative instruments, net of income taxes of ($4,337) and ($1,040)	(8,925)	(3,664)
Defined benefit plan adjustments, net of income taxes of $71	184
Foreign currency translation, net of income taxes of ($848) and ($2,811)	7,718	(30,012)
Reclassification adjustments:
Losses on derivative instruments included in net income, net of income taxes of $1,781 and $1,656	4,560	3,836
Amortization of actuarial losses included in net income, net of income taxes of $73 and $83	136	140
Comprehensive income	112,609	56,566
Comprehensive income attributable to noncontrolling interests	(333)	(30)
Comprehensive income attributable to Quintiles Transnational Holdings Inc.	$ 112,276	$ 56,536

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Unrealized losses on available-for-sale securities, income taxes	$ (56)	$ (104)
Unrealized losses on derivative instruments, income taxes	(4,337)	(1,040)
Defined benefit plan adjustments, income taxes	71
Foreign currency translation, income taxes	(848)	(2,811)
Losses on derivative instruments included in net income, income taxes	1,781	1,656
Amortization of actuarial losses included in net income, income taxes	$ 73	$ 83

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 1,053,212	$ 977,151
Restricted cash	3,566	2,478
Trade accounts receivable and unbilled services, net	1,175,597	1,165,749
Prepaid expenses	55,845	50,624
Deferred income taxes		100,978
Income taxes receivable	22,302	34,089
Investments in debt, equity and other securities	36,711
Other current assets and receivables	89,923	80,916
Total current assets	2,437,156	2,411,985
Property and equipment, net	189,011	188,393
Investments in debt, equity and other securities	32,765	32,911
Investments in unconsolidated affiliates	52,779	52,382
Goodwill	719,651	719,740
Other identifiable intangibles, net	362,260	368,106
Deferred income taxes	94,850	42,684
Deposits and other assets	94,467	110,115
Total assets	3,982,939	3,926,316
Current liabilities:
Accounts payable and accrued expenses	852,315	906,241
Unearned income	618,928	584,646
Income taxes payable	29,541	35,173
Current portion of long-term debt and obligations held under capital leases	48,517	48,513
Other current liabilities	28,837	19,603
Total current liabilities	1,578,138	1,594,176
Long-term debt and obligations held under capital leases, less current portion	2,408,555	2,419,293
Deferred income taxes	14,849	65,702
Other liabilities	187,338	182,826
Total liabilities	$ 4,188,880	$ 4,261,997
Commitments and contingencies
Shareholders’ deficit:
Common stock and additional paid-in capital, 300,000 shares authorized, $0.01 par value, 119,629 and 119,378 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively	$ 25,915	$ 8,784
Accumulated deficit	(354,967)	(461,635)
Accumulated other comprehensive loss	(105,758)	(111,366)
Deficit attributable to Quintiles Transnational Holdings Inc.’s shareholders	(434,810)	(564,217)
Noncontrolling interests	228,869	228,536
Total shareholders’ deficit	(205,941)	(335,681)
Total liabilities and shareholders’ deficit	$ 3,982,939	$ 3,926,316

CONDENSED CONSOLIDATED BALANCE6

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common stock, shares authorized	300,000,000	300,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares issued	119,629,000	119,378,000
Common stock, shares outstanding	119,629,000	119,378,000

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities:
Net income	$ 109,026	$ 86,431
Adjustments to reconcile net income to cash provided by (used in) operating activities:
Depreciation and amortization	31,724	30,329
Amortization of debt issuance costs and discount	1,686	1,677
Amortization of accumulated other comprehensive loss on terminated interest rate swaps	3,100
Share-based compensation	8,690	9,574
Loss (earnings) from unconsolidated affiliates	1,569	(911)
Provision for (benefit from) deferred income taxes	4,718	(884)
Excess income tax benefits from share-based award activities	(2,198)	(9,077)
Changes in operating assets and liabilities:
Change in accounts receivable, unbilled services and unearned income	22,575	(63,460)
Change in other operating assets and liabilities	(68,776)	(118,011)
Net cash provided by (used in) operating activities	112,114	(64,332)
Investing activities:
Acquisition of property, equipment and software	(26,199)	(16,432)
Purchase of trading securities	(36,941)
Proceeds from corporate owned life insurance policies	20,938
Investments in unconsolidated affiliates, net of payments received	(1,864)	(2,542)
Other	594	666
Net cash used in investing activities	(43,472)	(18,308)
Financing activities:
Payment of debt issuance costs		(19)
Repayment of debt and principal payments on capital lease obligations	(12,523)	(1,210)
Stock issued under employee stock purchase and option plans	5,335	18,494
Excess income tax benefits from share-based award activities	2,198	9,077
Net cash (used in) provided by financing activities	(4,990)	26,342
Effect of foreign currency exchange rate changes on cash	12,409	(31,992)
Increase (decrease) in cash and cash equivalents	76,061	(88,290)
Cash and cash equivalents at beginning of period	977,151	867,358
Cash and cash equivalents at end of period	$ 1,053,212	$ 779,068

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of Quintiles Transnational Holdings Inc. and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015. The balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP. Investments in Marketable Securities Investments in marketable securities are classified as either trading or available-for-sale and measured at fair market value. Realized and unrealized gains and losses on trading securities are included in other expense (income), net on the accompanying condensed consolidated statements of income. Realized gains and losses on available-for-sale securities are included in other expense (income), net on the accompanying condensed consolidated statements of income. Unrealized gains and losses, net of deferred income taxes, on available-for-sale securities are included in the accumulated other comprehensive income (loss) (“AOCI”) component of shareholders’ deficit until realized. Any gains or losses from the sales of investments or other-than-temporary declines in fair value are computed by specific identification. Recently Issued Accounting Standards Accounting pronouncement adopted In November 2015, the United States Financial Accounting Standards Board (“FASB”) issued new accounting guidance which removed the requirement that deferred income tax assets and liabilities be classified as either current or non-current in a classified statement of financial position and instead requires deferred income tax assets and liabilities to be classified as non-current. The Company adopted this new accounting guidance prospectively on January 1, 2016. Accounting pronouncements being evaluated In March 2016, the FASB issued new accounting guidance which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements, and the classification of excess tax benefits on the statement of cash flows. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In February 2016, the FASB issued new accounting guidance which requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. The income statement will reflect lease expense for operating leases, and amortization and interest expense for financing leases. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In January 2016, the FASB issued new accounting guidance which modifies how entities measure equity investments and present changes in the fair value of financial liabilities. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2017. Early adoption of the presentation guidance is permitted; however, early adoption of the recognition and measurement guidance is not permitted. The adoption of the new accounting guidance is not expected to have a material effect on the Company’s financial statements. In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition including information about changes in assets and liabilities that result from contracts with customers. The new standard allows for either a retrospective or prospective approach to transition upon adoption. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, the date of adoption, and the transition approach to implement the new standard.

Employee Stock Compensation

Employee Stock Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Employee Stock Compensation	2. Employee Stock Compensation The Company granted the following number of share-based awards: Three Months Ended March 31, 2016 2015 Stock options 744,300 923,700 Stock appreciation rights 25,200 176,200 Restricted stock units 289,771 226,821 Performance units 119,839 51,977 The Company had the following number of share-based awards outstanding: March 31, 2016 December 31, 2015 Stock options 7,188,849 6,647,999 Stock appreciation rights 555,901 530,701 Restricted stock units 598,931 359,553 Performance units 169,506 49,667 The Company used the following assumptions when estimating the value of the share-based compensation for stock options and stock appreciation rights issued as follows: Three Months Ended March 31, 2016 2015 Expected volatility 26 – 30% 30 – 41% Weighted average expected volatility 28% 35% Expected dividends 0.0% 0.0% Expected term (in years) 3.6 – 6.6 3.7 – 6.7 Risk-free interest rate 0.97 – 1.57% 1.06 – 1.88% The Company issued 52,772 shares and 38,449 shares of common stock for purchases under its employee stock purchase plan during the three months ended March 31, 2016 and 2015, respectively. The Company recognized share-based compensation expense of $8.7 million and $9.6 million during the three months ended March 31, 2016 and 2015, respectively.

Concentration of Credit Risk

Concentration of Credit Risk	3 Months Ended
	Mar. 31, 2016
Risks And Uncertainties [Abstract]
Concentration of Credit Risk	3. Concentration of Credit Risk No customer accounted for 10% or more of consolidated service revenues for the three months ended March 31, 2016 or 2015.

Accounts Receivable and Unbille

Accounts Receivable and Unbilled Services	3 Months Ended
	Mar. 31, 2016
Receivables [Abstract]
Accounts Receivable and Unbilled Services	4. Accounts Receivable and Unbilled Services Accounts receivable and unbilled services consist of the following (in thousands): March 31, 2016 December 31, 2015 Trade: Billed $ 531,303 $ 553,652 Unbilled services 648,625 614,381 1,179,928 1,168,033 Allowance for doubtful accounts (4,331 ) (2,284 ) $ 1,175,597 $ 1,165,749

Investments-Debt, Equity and Ot

Investments-Debt, Equity and Other Securities	3 Months Ended
	Mar. 31, 2016
Investments Debt And Equity Securities [Abstract]
Investments-Debt, Equity and Other Securities	5. Investments – Debt, Equity and Other Securities The following is a summary of the Company’s investments in debt, equity and other securities (in thousands): March 31, 2016 December 31, 2015 Marketable trading securities $ 36,711 $ — Marketable available-for-sale securities $ 249 $ 395 Cost method investments 32,516 32,516 $ 32,765 $ 32,911 Marketable Securities Trading securities consist primarily of investments in mutual funds and are measured at fair value with realized and unrealized gains and losses recorded in other expense (income), net on the accompanying condensed consolidated statements of income. Realized and unrealized gains, net of approximately $230,000 were recognized during the three months ended March 31, 2016. Available-for-sale securities consist of equity securities. Cost Method Investments On February 25, 2011, the Company and the Samsung Group entered into an agreement to form a joint venture intended to provide pharmaceutical contract manufacturing services in South Korea. On March 31, 2016, the parties amended the agreement to require the Company to exercise its right to sell a portion of its ownership interest in the joint venture to the Samsung Group under a notice effective as of April 22, 2016 in exchange for approximately $26.0 million. As of March 31, 2016, the Company’s investment in the joint venture totaled approximately $27.2 million (representing an ownership interest of approximately 2.2%). Following the closing of the sale, which is expected to occur in the second quarter, the Company’s investment will be reduced to approximately $1.2 million (representing an ownership interest of less than 1%). In December 2011, the Company and Intarcia Therapeutics (“Intarcia”) entered into an alliance to develop a new therapy for type 2 diabetes whereby Intarcia will use the Company to conduct Phase III pivotal clinical trials and a cardiovascular outcomes clinical trial. Under the alliance, the Company acquired $5.0 million of preferred stock of Intarcia.

Variable Interest Entities

Variable Interest Entities	3 Months Ended
	Mar. 31, 2016
Variable Interest Entity Disclosure [Abstract]
Variable Interest Entities	6. Variable Interest Entities As of March 31, 2016, the Company’s investments in unconsolidated variable interest entities (“VIEs”) and its estimated maximum exposure to loss were as follows (in thousands): Investments in Unconsolidated VIEs Maximum Exposure to Loss NovaQuest Pharma Opportunities Fund III, L.P. $ 39,320 $ 53,636 NovaQuest Pharma Opportunities Fund IV, L.P. 3,247 19,733 $ 42,567 $ 73,369 The Company has committed to invest up to $50 million as a limited partner in NovaQuest Pharma Opportunities Fund III, L.P. (“Fund III”). As of March 31, 2016, the Company has funded approximately $35.7 million and has approximately $14.3 million of remaining funding commitments. As of March 31, 2016 and December 31, 2015, the Company had a 10.9% ownership interest in Fund III. The Company’s maximum exposure to loss on Fund III is limited to its investment and remaining funding commitments. The Company has committed to invest up to $20 million as a limited partner in NovaQuest Pharma Opportunities Fund IV, L.P. (“Fund IV”). As of March 31, 2016, the Company has funded approximately $3.5 million and has approximately $16.5 million of remaining funding commitments. As of March 31, 2016 and December 31, 2015, the Company had a 2.3% ownership interest in Fund IV. The Company’s maximum exposure to loss on Fund IV is limited to its investment and remaining funding commitments. The Company has determined that Fund III and Fund IV (collectively “the Funds”) are VIEs but that the Company is not the primary beneficiary as it does not have a controlling financial interest in either of the Funds. Although the Company does not have a controlling financial interest in either of the Funds, the Company has determined that it has the ability to exercise significant influence. Accordingly, the Company accounts for its investments in the Funds as unconsolidated VIEs under the equity method of accounting and records its pro rata share of the Funds’ earnings or losses in equity in earnings (losses) of unconsolidated affiliates on the accompanying condensed consolidated statements of income. The investment assets of unconsolidated VIEs are included in investments in and advances to unconsolidated affiliates

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	7. Goodwill The following is a summary of goodwill by segment for the three months ended March 31, 2016 (in thousands): Integrated Product Healthcare Development Services Consolidated Balance as of December 31, 2015 $ 602,106 $ 117,634 $ 719,740 Impact of foreign currency fluctuations and other (1,836 ) 1,747 (89 ) Balance as of March 31, 2016 $ 600,270 $ 119,381 $ 719,651

Derivatives

Derivatives	3 Months Ended
	Mar. 31, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivatives	8. Derivatives As of March 31, 2016, the Company held the following derivative positions: (i) forward exchange contracts to protect against foreign exchange movements for certain forecasted foreign currency cash flows related to service contracts and (ii) interest rate swaps to hedge the exposure to variability in interest payments on variable interest rate debt. The Company does not use derivative financial instruments for speculative or trading purposes. As of March 31, 2016, the Company had 18 open foreign exchange forward contracts to hedge certain forecasted foreign currency cash flow transactions occurring in 2016 with notional amounts totaling $125.7 million. These contracts were executed to hedge the risk of the potential volatility in the cash flows resulting from fluctuations in currency exchange rates during the last nine months of 2016. These transactions are accounted for as cash flow hedges, as such, the effective portion of the gain or loss on the contracts is recorded as unrealized gains (losses) on derivatives included in AOCI. These hedges are highly effective. As of March 31, 2016 and December 31, 2015, the Company had recorded gross unrealized losses of $5.7 million and $5.2 million, respectively, related to foreign exchange forward contracts. Upon expiration of the hedge instruments in 2016, the Company will reclassify the unrealized holding gains and losses on the derivative instruments included in AOCI into earnings. The unrealized losses are included in other current liabilities on the accompanying condensed consolidated balance sheets as of March 31, 2016 and December 31, 2015. On June 3, 2015, the Company entered into seven forward starting interest rate swaps with a notional value of $440.0 million in an effort to limit its exposure to changes in the variable interest rate on its senior secured credit facilities. Interest on the swaps begins to accrue on June 30, 2016 and the interest rate swaps expire between March 31, 2017 and March 31, 2020. The critical terms of the interest rate swaps are substantially the same as those of the Company’s senior secured credit facilities, including quarterly interest settlements. These interest rate swaps are being accounted for as cash flow hedges as these transactions were executed to hedge the Company’s interest payments, and these hedges are deemed to be highly effective. As such, changes in the fair value of these derivative instruments are recorded as unrealized gains (losses) on derivatives included in AOCI. The fair value of these interest rate swaps represents the present value of the anticipated net payments the Company will make to the counterparty, which, when they occur, are reflected as interest expense on the condensed consolidated statements of income. These payments, together with the variable rate of interest incurred on the underlying debt, result in a fixed rate of interest of 2.1% plus the applicable margin on the affected borrowings. These interest rate swaps will result in a total debt mix of approximately 50% fixed rate debt and 50% variable rate debt. The Company expects that $4.8 million of unrealized losses will be reclassified out of AOCI and will form the interest rate swap component of the 2.1% fixed rate of interest incurred over the next 12 months as the underlying net payments are settled. The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands): Balance Sheet Classification March 31, 2016 December 31, 2015 Foreign exchange forward contracts Other current liabilities $ 5,721 $ 5,194 Interest rate swaps Other current liabilities $ 15,192 $ 5,698 The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands): Three Months Ended March 31, 2016 2015 Foreign exchange forward contracts $ (527 ) $ (1,689 ) Interest rate swaps (6,394 ) 2,477 Total $ (6,921 ) $ 788

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	9. Fair Value Measurements The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: · Level 1 — Quoted prices in active markets for identical assets or liabilities. · Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. · Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. Recurring Fair Value Measurements The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of March 31, 2016 (in thousands): Level 1 Level 2 Level 3 Total Assets: Trading securities $ 36,711 $ — $ — $ 36,711 Available-for-sale securities 249 — — 249 Total $ 36,960 $ — $ — $ 36,960 Liabilities: Foreign exchange forward contracts $ — $ 5,721 $ — $ 5,721 Interest rate swaps — 15,192 — 15,192 Contingent consideration — — 4,443 4,443 Total $ — $ 20,913 $ 4,443 $ 25,356 Below is a summary of the valuation techniques used in determining fair value: Marketable securities — The Company values trading and available-for-sale securities using the quoted market value of the securities held. Foreign exchange forward contracts — The Company values foreign exchange forward contracts using quoted market prices for identical instruments in less active markets or using other observable inputs. Interest rate swaps — The Company values interest rate swaps using market inputs with mid-market pricing as a practical expedient for bid-ask spread. Contingent consideration — The Company values contingent consideration related to business combinations using a weighted probability calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue, net new business and operating forecasts and the probability of achieving the specific targets. The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the three months ended March 31 (in thousands): Contingent Consideration – Accounts Payable and Accrued Expenses 2016 2015 Balance as of January 1 $ 4,374 $ 1,452 Revaluations included in earnings 69 1,287 Balance as of March 31 $ 4,443 $ 2,739 The revaluations for the contingent consideration are recognized in other expense (income), net on the accompanying condensed consolidated statements of income. Non-recurring Fair Value Measurements Certain assets are carried on the accompanying condensed consolidated balance sheets at cost and are not remeasured to fair value on a recurring basis. These assets include cost and equity method investments and loans that are written down to fair value for declines which are deemed to be other-than-temporary, and goodwill and identifiable intangible assets which are tested for impairment annually and when a triggering event occurs. As of March 31, 2016, assets carried on the balance sheet and not remeasured to fair value on a recurring basis totaling approximately $1,167.3 million and were identified as Level 3. These assets are comprised of cost and equity method investments of $85.3 million, goodwill of $719.7 million and other identifiable intangibles, net of $362.3 million.

Noncontrolling Interests

Noncontrolling Interests	3 Months Ended
	Mar. 31, 2016
Noncontrolling Interest [Abstract]
Noncontrolling Interests	10. Noncontrolling Interests Below is a summary of noncontrolling interests for the three months ended March 31 (in thousands): 2016 2015 Balance as of January 1 $ 228,536 $ 49 Comprehensive income (loss): Net income 2,358 33 Foreign currency adjustments, net of income tax (2,025 ) (2 ) Balance as of March 31 $ 228,869 $ 80

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2016
Restructuring And Related Activities [Abstract]
Restructuring	11. Restructuring 2016 Plan In February 2016, the Company’s Board of Directors (the “Board”) approved a restructuring plan for approximately $22 million, primarily for severance and other exit costs, to align its resources and reduce overcapacity. Some of these actions are subject to certain legal and regulatory requirements. These actions are expected to continue throughout 2016, and are expected to consist of severance, facility closure and other exit-related costs. 2015 Plans In February 2015 , the Board Since the start of this plan in 2015, the Company has recognized approximately $12.2 million, $8.9 million and $910,000 of restructuring costs related to this plan for activities in the Product Development segment, Integrated Healthcare Services segment and corporate activities, respectively. Also, in connection with consummating the joint venture transaction with Quest Diagnostics Incorporated, during the third quarter of 2015, a restructuring plan was approved to reduce facility overcapacity and eliminate redundant roles. These actions are expected to continue throughout 2016 and 2017, and are expected to consist of severance, facility closure and other exit-related costs of approximately $14.0 million. Since the start of this plan in 2015, the Company has recognized approximately $10.4 million of restructuring costs related to this plan for activities in the Product Development segment. The following amounts were recorded for the restructuring plans (in thousands): Severance and Related Costs Exit Costs Total Balance at December 31, 2015 $ 12,179 $ 1,385 $ 13,564 Expense, net of reversals 1,507 1,637 3,144 Payments (2,512 ) (80 ) (2,592 ) Foreign currency translation and other (494 ) 186 (308 ) Balance at March 31, 2016 $ 10,680 $ 3,128 $ 13,808 The reversals were due to changes in estimates primarily resulting from the redeployment of staff and higher than expected voluntary terminations. Restructuring costs are not allocated to the Company’s reportable segments as they are not part of the segment performance measures regularly reviewed by management. The Company expects the majority of the restructuring accruals at March 31, 2016 will be paid in 2016 and 2017.

Employee Benefit Plans

Employee Benefit Plans	3 Months Ended
	Mar. 31, 2016
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	12. Employee Benefit Plans Defined Benefit Plans The following table summarizes the components of pension expense related to the Company’s defined benefit plans (in thousands): Three Months Ended March 31, 2016 2015 Service cost $ 4,154 $ 3,614 Interest cost 919 867 Expected return on plan assets (871 ) (853 ) Amortization of actuarial losses 209 223 $ 4,411 $ 3,851 Other As of March 31, 2016 and December 31, 2015, the Company had a severance accrual included in accounts payable and accrued expenses on the accompanying condensed consolidated balance sheets of $2.8 million and $3.3 million, respectively. The Company recognizes obligations associated with severance related to contractual termination benefits at fair value on the date that it is probable that the affected employees will be entitled to the benefit and the amount can reasonably be estimated. The severance accrual is related to cost reduction programs that will result in severance for approximately 270 positions. During the first three months of 2016, the Company recognized approximately $537,000 of net reversals related to these cost reduction programs in the Product Development segment, primarily as a result of affected individuals transferring into other positions within the Company. The Company expects the majority of the severance accrual at March 31, 2016 will be paid in 2016. The following amounts were recorded for the severance associated with cost reduction programs (in thousands): Balance at December 31, 2015 $ 3,337 Expense, net of reversals (537 ) Foreign currency translation (26 ) Balance at March 31, 2016 $ 2,774

Comprehensive Income

Comprehensive Income	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Comprehensive Income	13. Comprehensive Income Below is a summary of the components of AOCI (in thousands): Foreign Currency Translation Available-for-Sale Securities Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2015 $ (116,830 ) $ (708 ) $ (13,992 ) $ (13,264 ) $ 33,428 $ (111,366 ) Other comprehensive (loss) income before reclassifications 8,895 (146 ) (13,262 ) 255 5,170 912 Reclassification adjustments — — 6,341 209 (1,854 ) 4,696 Balance at March 31, 2016 $ (107,935 ) $ (854 ) $ (20,913 ) $ (12,800 ) $ 36,744 $ (105,758 ) Below is a summary of the (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item (in thousands): Affected Financial Statement Three Months Ended March 31, Reclassification Adjustments Line Item 2016 2015 Derivative instruments: Interest rate swaps Interest expense $ 3,100 $ 3,013 Foreign exchange forward contracts Service revenues 3,241 2,479 Total before income taxes 6,341 5,492 Income tax benefit 1,781 1,656 Total net of income taxes $ 4,560 $ 3,836 Defined benefit plans: Amortization of actuarial losses See Note 12 $ 209 $ 223 Total before income taxes 209 223 Income tax benefit 73 83 Total net of income taxes $ 136 $ 140

Segments

Segments	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Segments	14. Segments The following table presents the Company’s operations by reportable segment. The Company is managed through two reportable segments, Product Development and Integrated Healthcare Services. Product Development, which primarily serves biopharmaceutical customers engaged in research and development, provides clinical research and clinical trial services. Integrated Healthcare Services provides commercialization services to biopharmaceutical customers and research, analytics, real-world and late phase research, and other services to both biopharmaceutical customers and the broader healthcare market. Certain costs are not allocated to the Company’s segments and are reported as general corporate and unallocated expenses. These costs primarily consist of share-based compensation and expenses for corporate overhead functions such as senior leadership, finance, human resources, information technology, facilities and legal. The Company does not allocate restructuring charges to its segments. Information presented below is in thousands: Three Months Ended March 31, 2016 2015 Service revenues Product Development $ 837,479 $ 749,529 Integrated Healthcare Services 270,543 280,445 Total service revenues 1,108,022 1,029,974 Costs of revenue, service costs Product Development 484,640 437,422 Integrated Healthcare Services 215,926 224,405 Total costs of revenue, service costs 700,566 661,827 Selling, general and administrative Product Development 163,553 155,108 Integrated Healthcare Services 36,691 37,922 General corporate and unallocated 25,272 26,576 Total selling, general and administrative 225,516 219,606 Income from operations Product Development 189,286 156,999 Integrated Healthcare Services 17,926 18,118 General corporate and unallocated (25,272 ) (26,576 ) Restructuring costs (3,144 ) (5,324 ) Total income from operations $ 178,796 $ 143,217 Three Months Ended March 31, 2016 2015 Depreciation and amortization expense Product Development $ 26,230 $ 23,876 Integrated Healthcare Services 4,257 5,208 General corporate and unallocated 1,237 1,245 Total depreciation and amortization expense $ 31,724 $ 30,329

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share	15. Earnings Per Share The following table shows the weighted average number of outstanding share-based awards not included in the computation of diluted earnings per share as the effect of including such share-based awards in the computation would be anti-dilutive (in thousands): Three Months Ended March 31, 2016 2015 Weighted average shares subject to anti-dilutive share-based awards 1,383 1,043 Share-based awards will have a dilutive effect under the treasury method only when the respective period’s average market value of the Company’s common stock exceeds the exercise proceeds.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Event On May 3, 2016, the Company entered into Agreement and Plan of Merger (the “Merger Agreement”) with IMS Health Holdings, Inc., a Delaware corporation (“IMS”). Subject to the terms and conditions of the Merger Agreement, which was unanimously approved by the boards of directors of the Company and IMS, the Company and IMS have agreed that IMS will merge with and into the Company in a “merger of equals,” with the Company continuing as the surviving corporation (the “Surviving Corporation”) and the separate corporate existence of IMS ceasing (the “Merger”).

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of Quintiles Transnational Holdings Inc. and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015. The balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP.
Investments in Marketable Securities	Investments in Marketable Securities Investments in marketable securities are classified as either trading or available-for-sale and measured at fair market value. Realized and unrealized gains and losses on trading securities are included in other expense (income), net on the accompanying condensed consolidated statements of income. Realized gains and losses on available-for-sale securities are included in other expense (income), net on the accompanying condensed consolidated statements of income. Unrealized gains and losses, net of deferred income taxes, on available-for-sale securities are included in the accumulated other comprehensive income (loss) (“AOCI”) component of shareholders’ deficit until realized. Any gains or losses from the sales of investments or other-than-temporary declines in fair value are computed by specific identification.
Recently Issued Accounting Standards	Recently Issued Accounting Standards Accounting pronouncement adopted In November 2015, the United States Financial Accounting Standards Board (“FASB”) issued new accounting guidance which removed the requirement that deferred income tax assets and liabilities be classified as either current or non-current in a classified statement of financial position and instead requires deferred income tax assets and liabilities to be classified as non-current. The Company adopted this new accounting guidance prospectively on January 1, 2016. Accounting pronouncements being evaluated In March 2016, the FASB issued new accounting guidance which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements, and the classification of excess tax benefits on the statement of cash flows. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In February 2016, the FASB issued new accounting guidance which requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. The income statement will reflect lease expense for operating leases, and amortization and interest expense for financing leases. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In January 2016, the FASB issued new accounting guidance which modifies how entities measure equity investments and present changes in the fair value of financial liabilities. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2017. Early adoption of the presentation guidance is permitted; however, early adoption of the recognition and measurement guidance is not permitted. The adoption of the new accounting guidance is not expected to have a material effect on the Company’s financial statements. In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition including information about changes in assets and liabilities that result from contracts with customers. The new standard allows for either a retrospective or prospective approach to transition upon adoption. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, the date of adoption, and the transition approach to implement the new standard.

Employee Stock Compensation (Ta

Employee Stock Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Number of Share-Based Awards Granted and Outstanding	The Company granted the following number of share-based awards: Three Months Ended March 31, 2016 2015 Stock options 744,300 923,700 Stock appreciation rights 25,200 176,200 Restricted stock units 289,771 226,821 Performance units 119,839 51,977 The Company had the following number of share-based awards outstanding: March 31, 2016 December 31, 2015 Stock options 7,188,849 6,647,999 Stock appreciation rights 555,901 530,701 Restricted stock units 598,931 359,553 Performance units 169,506 49,667
Assumptions Used to Estimate Value of Share-Based Compensation for Stock Options and Stock Appreciation Rights Issued	The Company used the following assumptions when estimating the value of the share-based compensation for stock options and stock appreciation rights issued as follows: Three Months Ended March 31, 2016 2015 Expected volatility 26 – 30% 30 – 41% Weighted average expected volatility 28% 35% Expected dividends 0.0% 0.0% Expected term (in years) 3.6 – 6.6 3.7 – 6.7 Risk-free interest rate 0.97 – 1.57% 1.06 – 1.88%

Accounts Receivable and Unbil26

Accounts Receivable and Unbilled Services (Tables)	3 Months Ended
	Mar. 31, 2016
Receivables [Abstract]
Accounts Receivable and Unbilled Services	Accounts receivable and unbilled services consist of the following (in thousands): March 31, 2016 December 31, 2015 Trade: Billed $ 531,303 $ 553,652 Unbilled services 648,625 614,381 1,179,928 1,168,033 Allowance for doubtful accounts (4,331 ) (2,284 ) $ 1,175,597 $ 1,165,749

Investments-Debt, Equity and 27

Investments-Debt, Equity and Other Securities (Tables)	3 Months Ended
	Mar. 31, 2016
Investments Debt And Equity Securities [Abstract]
Summary of the Company's Investments in Debt, Equity and Other Securities	The following is a summary of the Company’s investments in debt, equity and other securities (in thousands): March 31, 2016 December 31, 2015 Marketable trading securities $ 36,711 $ — Marketable available-for-sale securities $ 249 $ 395 Cost method investments 32,516 32,516 $ 32,765 $ 32,911

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	3 Months Ended
	Mar. 31, 2016
Variable Interest Entity Disclosure [Abstract]
Summary of Investments in Unconsolidated Variable Interest Entities and Estimated Maximum Exposure to Loss	As of March 31, 2016, the Company’s investments in unconsolidated variable interest entities (“VIEs”) and its estimated maximum exposure to loss were as follows (in thousands): Investments in Unconsolidated VIEs Maximum Exposure to Loss NovaQuest Pharma Opportunities Fund III, L.P. $ 39,320 $ 53,636 NovaQuest Pharma Opportunities Fund IV, L.P. 3,247 19,733 $ 42,567 $ 73,369

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Goodwill by Segment	The following is a summary of goodwill by segment for the three months ended March 31, 2016 (in thousands): Integrated Product Healthcare Development Services Consolidated Balance as of December 31, 2015 $ 602,106 $ 117,634 $ 719,740 Impact of foreign currency fluctuations and other (1,836 ) 1,747 (89 ) Balance as of March 31, 2016 $ 600,270 $ 119,381 $ 719,651

Derivatives (Tables)

Derivatives (Tables)	3 Months Ended
	Mar. 31, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Summary of Fair Values of Derivative Instruments Designated as Hedges	The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands): Balance Sheet Classification March 31, 2016 December 31, 2015 Foreign exchange forward contracts Other current liabilities $ 5,721 $ 5,194 Interest rate swaps Other current liabilities $ 15,192 $ 5,698
Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss)	The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands): Three Months Ended March 31, 2016 2015 Foreign exchange forward contracts $ (527 ) $ (1,689 ) Interest rate swaps (6,394 ) 2,477 Total $ (6,921 ) $ 788

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of March 31, 2016 (in thousands): Level 1 Level 2 Level 3 Total Assets: Trading securities $ 36,711 $ — $ — $ 36,711 Available-for-sale securities 249 — — 249 Total $ 36,960 $ — $ — $ 36,960 Liabilities: Foreign exchange forward contracts $ — $ 5,721 $ — $ 5,721 Interest rate swaps — 15,192 — 15,192 Contingent consideration — — 4,443 4,443 Total $ — $ 20,913 $ 4,443 $ 25,356
Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the three months ended March 31 (in thousands): Contingent Consideration – Accounts Payable and Accrued Expenses 2016 2015 Balance as of January 1 $ 4,374 $ 1,452 Revaluations included in earnings 69 1,287 Balance as of March 31 $ 4,443 $ 2,739

Noncontrolling Interests (Table

Noncontrolling Interests (Tables)	3 Months Ended
	Mar. 31, 2016
Noncontrolling Interest [Abstract]
Summary of Noncontrolling Interests	Below is a summary of noncontrolling interests for the three months ended March 31 (in thousands): 2016 2015 Balance as of January 1 $ 228,536 $ 49 Comprehensive income (loss): Net income 2,358 33 Foreign currency adjustments, net of income tax (2,025 ) (2 ) Balance as of March 31 $ 228,869 $ 80

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2016
Restructuring And Related Activities [Abstract]
Summary of Amounts Recorded for Restructuring Plans	The following amounts were recorded for the restructuring plans (in thousands): Severance and Related Costs Exit Costs Total Balance at December 31, 2015 $ 12,179 $ 1,385 $ 13,564 Expense, net of reversals 1,507 1,637 3,144 Payments (2,512 ) (80 ) (2,592 ) Foreign currency translation and other (494 ) 186 (308 ) Balance at March 31, 2016 $ 10,680 $ 3,128 $ 13,808

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	3 Months Ended
	Mar. 31, 2016
Compensation And Retirement Disclosure [Abstract]
Summary of Components of Pension Expenses Related to Defined Benefit Plans	The following table summarizes the components of pension expense related to the Company’s defined benefit plans (in thousands): Three Months Ended March 31, 2016 2015 Service cost $ 4,154 $ 3,614 Interest cost 919 867 Expected return on plan assets (871 ) (853 ) Amortization of actuarial losses 209 223 $ 4,411 $ 3,851
Summary of Severance Associated with Cost Reduction Programs	The following amounts were recorded for the severance associated with cost reduction programs (in thousands): Balance at December 31, 2015 $ 3,337 Expense, net of reversals (537 ) Foreign currency translation (26 ) Balance at March 31, 2016 $ 2,774

Comprehensive Income (Tables)

Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Summary of Components of AOCI	Below is a summary of the components of AOCI (in thousands): Foreign Currency Translation Available-for-Sale Securities Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2015 $ (116,830 ) $ (708 ) $ (13,992 ) $ (13,264 ) $ 33,428 $ (111,366 ) Other comprehensive (loss) income before reclassifications 8,895 (146 ) (13,262 ) 255 5,170 912 Reclassification adjustments — — 6,341 209 (1,854 ) 4,696 Balance at March 31, 2016 $ (107,935 ) $ (854 ) $ (20,913 ) $ (12,800 ) $ 36,744 $ (105,758 )
Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item	Below is a summary of the (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item (in thousands): Affected Financial Statement Three Months Ended March 31, Reclassification Adjustments Line Item 2016 2015 Derivative instruments: Interest rate swaps Interest expense $ 3,100 $ 3,013 Foreign exchange forward contracts Service revenues 3,241 2,479 Total before income taxes 6,341 5,492 Income tax benefit 1,781 1,656 Total net of income taxes $ 4,560 $ 3,836 Defined benefit plans: Amortization of actuarial losses See Note 12 $ 209 $ 223 Total before income taxes 209 223 Income tax benefit 73 83 Total net of income taxes $ 136 $ 140

Segments (Tables)

Segments (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Reconciliation of Revenues and Income from Segments to Consolidated	Information presented below is in thousands: Three Months Ended March 31, 2016 2015 Service revenues Product Development $ 837,479 $ 749,529 Integrated Healthcare Services 270,543 280,445 Total service revenues 1,108,022 1,029,974 Costs of revenue, service costs Product Development 484,640 437,422 Integrated Healthcare Services 215,926 224,405 Total costs of revenue, service costs 700,566 661,827 Selling, general and administrative Product Development 163,553 155,108 Integrated Healthcare Services 36,691 37,922 General corporate and unallocated 25,272 26,576 Total selling, general and administrative 225,516 219,606 Income from operations Product Development 189,286 156,999 Integrated Healthcare Services 17,926 18,118 General corporate and unallocated (25,272 ) (26,576 ) Restructuring costs (3,144 ) (5,324 ) Total income from operations $ 178,796 $ 143,217
Depreciation and Amortization Expense	Three Months Ended March 31, 2016 2015 Depreciation and amortization expense Product Development $ 26,230 $ 23,876 Integrated Healthcare Services 4,257 5,208 General corporate and unallocated 1,237 1,245 Total depreciation and amortization expense $ 31,724 $ 30,329

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Summary of Weighted-Average Outstanding Stock Options Excluded from Computation of Diluted Earnings Per Share	The following table shows the weighted average number of outstanding share-based awards not included in the computation of diluted earnings per share as the effect of including such share-based awards in the computation would be anti-dilutive (in thousands): Three Months Ended March 31, 2016 2015 Weighted average shares subject to anti-dilutive share-based awards 1,383 1,043

Employee Stock Compensation - S

Employee Stock Compensation - Schedule of Number of Share-Based Awards Granted and Outstanding (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	744,300	923,700
Stock options outstanding	7,188,849		6,647,999
Stock Appreciation Rights Granted [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity Instruments Other than Options, Grants	25,200	176,200
Equity Instruments Other than Options, Outstanding	555,901		530,701
Restricted Stock Units Granted [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity Instruments Other than Options, Grants	289,771	226,821
Equity Instruments Other than Options, Outstanding	598,931		359,553
Performance Units Granted [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity Instruments Other than Options, Grants	119,839	51,977
Equity Instruments Other than Options, Outstanding	169,506		49,667

Employee Stock Compensation - A

Employee Stock Compensation - Assumptions Used to Estimate Value of Share-Based Compensation for Stock Options and Stock Appreciation Rights Issued (Detail)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected volatility, Minimum	26.00%	30.00%
Expected volatility, Maximum	30.00%	41.00%
Weighted average expected volatility	28.00%	35.00%
Expected dividends	0.00%	0.00%
Risk-free interest rate, Minimum	0.97%	1.06%
Risk-free interest rate, Maximum	1.57%	1.88%
Minimum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected term (in years)	3 years 7 months 6 days	3 years 8 months 12 days
Maximum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected term (in years)	6 years 7 months 6 days	6 years 8 months 12 days

Employee Stock Compensation -40

Employee Stock Compensation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 8,690	$ 9,574
Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares issued for purchases under employee stock purchase plan	52,772	38,449

Concentration of Credit Risk -

Concentration of Credit Risk - Additional Information (Detail) - Customer	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Risks And Uncertainties [Abstract]
Number of customers served	0	0

Accounts Receivable and Unbil42

Accounts Receivable and Unbilled Services - Accounts Receivable and Unbilled Services (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Trade:
Billed	$ 531,303	$ 553,652
Unbilled services	648,625	614,381
Trade accounts receivable and unbilled services, gross	1,179,928	1,168,033
Allowance for doubtful accounts	(4,331)	(2,284)
Trade accounts receivable and unbilled services, net	$ 1,175,597	$ 1,165,749

Investments - Debt, Equity and

Investments - Debt, Equity and Other Securities - Summary of the Company's Investments in Debt, Equity and Other Securities (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Investments Debt And Equity Securities [Abstract]
Marketable trading securities	$ 36,711
Marketable available-for-sale securities	249	$ 395
Cost method investments	32,516	32,516
Total	$ 32,765	$ 32,911

Investments - Debt, Equity an44

Investments - Debt, Equity and Other Securities - Additional Information (Detail) - USD ($)	Apr. 22, 2016	Mar. 31, 2016	Jun. 30, 2016
Investments Debt And Equity Securities [Line Items]
Realized and unrealized gains, net		$ 230,000
Investment in joint venture		$ 27,200,000
Non controlling interest percentage in exchange of investment in joint venture		2.20%
Preferred stock acquired from Intarcia		$ 5,000,000
Subsequent Event [Member]
Investments Debt And Equity Securities [Line Items]
Proceeds from sale of ownership interest in joint venture	$ 26,000,000
Scenario Forecast [Member]
Investments Debt And Equity Securities [Line Items]
Investment in joint venture			$ 1,200,000
Scenario Forecast [Member] | Maximum [Member]
Investments Debt And Equity Securities [Line Items]
Non controlling interest percentage in exchange of investment in joint venture			1.00%

Variable Interest Entities - Su

Variable Interest Entities - Summary of Investments in Unconsolidated Variable Interest Entities and Estimated Maximum Exposure to Loss (Detail)	Mar. 31, 2016USD ($)
Variable Interest Entity [Line Items]
Investments in Unconsolidated VIEs	$ 42,567,000
Maximum Exposure to Loss	73,369,000
NovaQuest Pharma Opportunities Fund lll, L.P [Member]
Variable Interest Entity [Line Items]
Investments in Unconsolidated VIEs	39,320,000
Maximum Exposure to Loss	53,636,000
NovaQuest Pharma Opportunities Fund lV, L.P [Member]
Variable Interest Entity [Line Items]
Investments in Unconsolidated VIEs	3,247,000
Maximum Exposure to Loss	$ 19,733,000

Variable Interest Entities - Ad

Variable Interest Entities - Additional Information (Detail) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
NovaQuest Pharma Opportunities Fund lll, L.P [Member]
Variable Interest Entity [Line Items]
Committed to invest fund	$ 50
Commitment funded	35.7
Funding commitments	$ 14.3
Beneficial ownership in common stock	10.90%	10.90%
NovaQuest Pharma Opportunities Fund lV, L.P [Member]
Variable Interest Entity [Line Items]
Committed to invest fund	$ 20
Commitment funded	3.5
Funding commitments	$ 16.5
Beneficial ownership in common stock	2.30%	2.30%

Goodwill - Summary of Goodwill

Goodwill - Summary of Goodwill by Segment (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Goodwill [Line Items]
Beginning Balance	$ 719,740
Impact of foreign currency fluctuations and other	(89)
Ending Balance	719,651
Product Development [Member]
Goodwill [Line Items]
Beginning Balance	602,106
Impact of foreign currency fluctuations and other	(1,836)
Ending Balance	600,270
Integrated Healthcare Services [Member]
Goodwill [Line Items]
Beginning Balance	117,634
Impact of foreign currency fluctuations and other	1,747
Ending Balance	$ 119,381

Derivatives - Additional Inform

Derivatives - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Mar. 31, 2016USD ($)Derivative	Dec. 31, 2015USD ($)	Jun. 03, 2015USD ($)Agreement
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of foreign exchange forward contracts | Agreement			7
Notional amount			$ 440,000,000
Interest swaps accrual beginning date	Jun. 30, 2016
Derivative fixed interest rate	2.10%
Interest rate cash flow hedge loss to be reclassified during next 12 months, net	$ 4,800,000
Senior Notes [Member] | Variable Rate Debt [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps effectively converted percent	50.00%
Senior Notes [Member] | Fixed Rate Debt [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps effectively converted percent	50.00%
Foreign Exchange Forward Contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of foreign exchange forward contracts | Derivative	18
Notional amount	$ 125,700,000
Losses related to these foreign exchange forward contracts	$ 5,700,000	$ 5,200,000
Expiration year of hedge instruments	2,016
Seven Interest Rate Swaps [Member] | Minimum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date	Mar. 31, 2017
Seven Interest Rate Swaps [Member] | Maximum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date	Mar. 31, 2020

Derivatives - Summary of Fair V

Derivatives - Summary of Fair Values of Derivative Instruments Designated as Hedges (Detail) - Designated as Hedging Instrument [Member] - Other Current Liabilities [Member] - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Foreign Exchange Forward Contracts [Member]
Derivatives Fair Value [Line Items]
Derivative liability fair value	$ 5,721	$ 5,194
Interest Rate Swaps [Member]
Derivatives Fair Value [Line Items]
Derivative liability fair value	$ 15,192	$ 5,698

Derivatives - Effect of Cash Fl

Derivatives - Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss) (Detail) - Derivatives Designated As Cash Flow Hedges [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$ (6,921)	$ 788
Foreign Exchange Forward Contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	(527)	(1,689)
Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$ (6,394)	$ 2,477

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Recurring Fair Value Measurements [Member] $ in Thousands	Mar. 31, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 36,960
Fair value of liabilities	25,356
Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	5,721
Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	15,192
Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	4,443
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	36,960
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	20,913
Level 2 [Member] | Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	5,721
Level 2 [Member] | Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	15,192
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	4,443
Level 3 [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	4,443
Available-for-sale Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	249
Available-for-sale Securities [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	249
Trading Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	36,711
Trading Securities [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 36,711

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Accounts Payable and Accrued Expenses [Member] - Contingent Consideration [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance, Contingent Consideration	$ 4,374	$ 1,452
Revaluations included in earnings	69	1,287
Ending Balance, Contingent Consideration	$ 4,443	$ 2,739

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other identifiable intangibles, net	$ 362,260	$ 368,106
Non-recurring Fair Value Measurements [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	1,167,300
Cost and equity method investments	85,300
Goodwill	719,700
Other identifiable intangibles, net	$ 362,300

Noncontrolling Interests - Summ

Noncontrolling Interests - Summary of Noncontrolling Interests (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Noncontrolling Interest [Abstract]
Beginning Balance	$ 228,536	$ 49
Comprehensive income (loss):
Net income	2,358	33
Foreign currency adjustments, net of income tax	(2,025)	(2)
Ending Balance	$ 228,869	$ 80

Restructuring - Additional Info

Restructuring - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Sep. 30, 2015	Mar. 31, 2015	Feb. 29, 2016	Feb. 28, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 3,144,000		$ 5,324,000
Quest [Member]
Restructuring Cost and Reserve [Line Items]
Severance, facility closure and other exit-related costs		$ 14,000,000
2016 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring plan approved				$ 22,000,000
2016 Plan [Member] | Operating Segments [Member] | Product Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	977,000
2015 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring plan approved					$ 30,000,000
2015 Plan [Member] | Operating Segments [Member] | Product Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	12,200,000
2015 Plan [Member] | Operating Segments [Member] | Product Development [Member] | Quest [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	10,400,000
2015 Plan [Member] | Operating Segments [Member] | Integrated Healthcare Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	8,900,000
2015 Plan [Member] | Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 910,000

Restructuring - Summary of Amou

Restructuring - Summary of Amounts Recorded for Restructuring Plans (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance	$ 13,564
Expense, net of reversals	3,144	$ 5,324
Payments	(2,592)
Foreign currency translation and other	(308)
Restructuring reserves, ending balance	13,808
Severance and Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance	12,179
Expense, net of reversals	1,507
Payments	(2,512)
Foreign currency translation and other	(494)
Restructuring reserves, ending balance	10,680
Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance	1,385
Expense, net of reversals	1,637
Payments	(80)
Foreign currency translation and other	186
Restructuring reserves, ending balance	$ 3,128

Employee Benefit Plans - Summar

Employee Benefit Plans - Summary of Components of Pension Expenses Related to Defined Benefit Plans (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Service cost	$ 4,154	$ 3,614
Interest cost	919	867
Expected return on plan assets	(871)	(853)
Amortization of actuarial losses	209	223
Total pension expense related to defined benefit plans	$ 4,411	$ 3,851

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016USD ($)Position	Dec. 31, 2015USD ($)
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expenses payable	$ 2,774,000	$ 3,337,000
Number of positions expected to be eliminated | Position	270
Severance expense, net of reversals	$ (537,000)
Product Development [Member]
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expense, net of reversals	$ (537,000)

Employee Benefit Plans - Summ59

Employee Benefit Plans - Summary of Severance Associated with Cost Reduction Programs (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Compensation And Retirement Disclosure [Abstract]
Severance expenses payable, opening balance	$ 3,337
Severance expense, net of reversals	(537)
Severance foreign currency translation	(26)
Severance expenses payable, ending balance	$ 2,774

Comprehensive Income - Summary

Comprehensive Income - Summary of Components of AOCI (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ 33,428
Other comprehensive (loss) income before reclassifications, tax	5,170
Reclassification adjustments, tax	(1,854)
Ending Balance	36,744
Beginning Balance	(564,217)
Ending Balance	(434,810)
Foreign Currency Translation [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(116,830)
Other comprehensive (loss) income before reclassifications, before tax	8,895
Ending Balance	(107,935)
Available-for-Sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(708)
Other comprehensive (loss) income before reclassifications, before tax	(146)
Ending Balance	(854)
Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(13,992)
Other comprehensive (loss) income before reclassifications, before tax	(13,262)
Reclassification adjustments, before tax	6,341
Ending Balance	(20,913)
Defined Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(13,264)
Other comprehensive (loss) income before reclassifications, before tax	255
Reclassification adjustments, before tax	209
Ending Balance	(12,800)
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(111,366)
Other comprehensive (loss) income before reclassifications, net of tax	912
Reclassification adjustments, net of tax	4,696
Ending Balance	$ (105,758)

Comprehensive Income - Summar61

Comprehensive Income - Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	$ 6,341	$ 5,492
Income tax benefit	1,781	1,656
Total net of income taxes	4,560	3,836
Amortization of actuarial losses	209	223
Total before income taxes	209	223
Income tax benefit	73	83
Total net of income taxes	136	140
Interest Rate Swaps [Member] | Interest Expense [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	3,100	3,013
Foreign Exchange Forward Contracts [Member] | Service Revenues [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	$ 3,241	$ 2,479

Segments - Additional Informati

Segments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segments - Operations by Report

Segments - Operations by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Service revenues	$ 1,108,022	$ 1,029,974
Costs of revenue, service costs	700,566	661,827
Selling, general and administrative	225,516	219,606
Income from operations	178,796	143,217
Restructuring costs	(3,144)	(5,324)
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Service revenues	837,479	749,529
Costs of revenue, service costs	484,640	437,422
Selling, general and administrative	163,553	155,108
Income from operations	189,286	156,999
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Service revenues	270,543	280,445
Costs of revenue, service costs	215,926	224,405
Selling, general and administrative	36,691	37,922
Income from operations	17,926	18,118
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	25,272	26,576
Income from operations	$ (25,272)	$ (26,576)

Segments - Depreciation and Amo

Segments - Depreciation and Amortization Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 31,724	$ 30,329
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization	26,230	23,876
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization	4,257	5,208
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 1,237	$ 1,245

Earnings Per Share - Summary of

Earnings Per Share - Summary of Weighted-Average Outstanding Share-Based Awards Excluded from Computation of Diluted Earnings Per Share (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Earnings Per Share [Abstract]
Weighted average shares subject to anti-dilutive share-based awards	1,383	1,043

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - IMS Health Holdings, Inc. [Member] - Subsequent Event [Member]	May. 03, 2016
Subsequent Event [Line Items]
Merger agreement, date of merger agreement	May 3, 2016
Merger agreement estimate closing period	second half of 2016
Common Stock [Member]
Subsequent Event [Line Items]
Merger agreement, convertible share conversion ratio	0.3840